KALA BIO, Inc. (KALA)

6.75 -0.20 (-2.81%) At close: 04:00PM EDT

KALA BIO, Inc.

1167 Massachusetts Avenue
Arlington, MA 02476
United States
781 996 5252
https://www.kalarx.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 43

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Mark T. Iwicki	Chairman & CEO	1.1M	N/A	1966
Mr. Todd Bazemore	President & COO	783.04k	N/A	1970
Dr. Kim Brazzell Ph.D.	Head of R&D and Chief Medical Officer	750.91k	N/A	1953
Dr. Justin Hanes Ph.D.	Founder & Chair of the Scientific Advisory Board	N/A	N/A	N/A
Ms. Mary Reumuth CPA	CFO & Treasurer	N/A	N/A	1975
Ms. Jill S. Steier	Executive Director of Investor Relations & Corporate Communications	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.

Corporate governance

KALA BIO, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.